Disclosure Devil - Summary

QUARTERLY STATEMENT 3rd quarter | First nine months A WEAK THIRD QUARTER 3rd quarter  Considerable slowing of business due to global economic conditions  Lower volumes but virtually stable selling prices  Adjusted EBITDA 22 percent lower at €448 million 1st nine months  Adjusted EBITDA declined by 10 percent to €1,517 million  Adjusted EBITDA margin slipped slightly to 14.2 percent  Net income 34 percent lower at €247 million  Free cash flow decreased to €284 million  Outlook for 2025 revised: Adjusted EBITDA now expected to be around €1.9 billion Key figures for the Evonik Group 3rd quarter 1st nine months in € million 2024 2025 2024 2025 Sales 3,832 3,391 11,558 10,666 Adjusted EBITDAa 577 448 1,677 1,517 Adjusted EBITDA margin in % 15.1 13.2 14.5 14.2 Adjusted EBITb 322 197 916 756 Income before financial result and income taxes, continuing operations (EBIT) 322 -25 667 510 Net income 223 -106 374 247 Adjusted net income 271 128 702 563 Earnings per share in € 0.48 -0.23 0.80 0.53 Adjusted earnings per share in € 0.58 0.27 1.51 1.21 Cash flow from operating activities, continuing operations 537 481 1,275 831 Cash outflows for investments in intangible assets, property, plant and equipment -180 -181 -574 -547 Free cash flowc 357 300 701 284 Net financial debt as of September 30 – – -3,286 -3,677 No. of employees as of September 30 – – 32,040 31,297 a Earnings before financial result, taxes, depreciation, and amortization, after adjustments, continuing operations. b Earnings before financial result and taxes, after adjustments, continuing operations. c Cash flow from operating activities, continuing operations, less cash outflows for investments in intangible assets, property, plant and equipment. Due to rounding, some figures in this report may not add up exactly to the totals stated. CONTENTS Business conditions and performance 2 Business performance 2 Performance of the segments 5 Financial position 9 Expected development 10 Income statement 13 Balance sheet 14 Cash flow statement 15 Segment report 16 Appendix 20 Financial calendar 22 Credits 22 Advanced Technologies 43% Custom Solutions 39% Infrastructure 18% Sales by segment—1st nine months 2025 Europe, Middle East & Africa 48% Americas 29% Asia-Pacific 23% Sales by regiona—1st nine months 2025 a By location of customer. 2 QUARTERLY STATEMENT Q3 2025 EVONIK Business conditions and performance Business performance Business performance in Q3 2025 Following a good start to 2025, the increasingly challenging global macroeconomic conditions had a considerable impact on our business. The earnings downturn that started in the second quarter continued in the third quarter. Customers in all segments and almost all end-markets are very cautious. Sales and adjusted EBITDA declined, principally as a result of weaker demand. The Evonik Group’s sales fell 12 percent to €3,391 million. The organic decline in sales of 7 percent resulted from considerably lower volumes, while selling prices were virtually unchanged. In addition, sales were reduced by negative currency effects as well as by the sale of the Superabsorbents business as of August 31, 2024. Year-on-year change in sales in % 1st quarter 2025 2nd quarter 2025 3rd quarter 2025 1st nine months 2025 Volumes 2 -4 -6 -3 Prices -2 -1 -1 -1 Organic change in sales – -5 -7 -4 Exchange rates 1 -3 -3 -2 Change in the scope of consolidation/other effects -2 -3 -2 -2 Total -1 -11 -12 -8 3,599 3,832 3,930 3,796 3,391 3,499 3,777 0 600 1,200 1,800 2,400 3,000 3,600 4,200 Q4 Q3 Q2 Q1 Sales by quarter 2025 2024 in € million EVONIK QUARTERLY STATEMENT Q3 2025 3 Adjusted EBITDA decreased by 22 percent to €448 million. This was due to the considerable drop in demand and lower selling prices. By contrast, the reduction in variable costs supported earnings. The adjusted EBITDA margin fell from 15.1 percent in the third quarter of 2024 to 13.2 percent. Statement of income 3rd quarter 1st nine months in € million 2024 2025 Change in % 2024 2025 Change in % Sales 3,832 3,391 -12 11,558 10,666 -8 Adjusted EBITDA 577 448 -22 1,677 1,517 -10 Adjusted depreciation, amortization, and impairment losses -255 -251 -761 -761 Adjusted EBIT 322 197 -39 916 756 -17 Adjustments – -222 -249 -246 thereof structural measures -2 -31 -231 -36 thereof acquisitions and divestments -18 – -31 -7 thereof other special items 20 -191 13 -203 Income before financial result and income taxes, continuing operations (EBIT) 322 -25 – 667 510 -24 Financial result -48 -52 -112 -126 Income before income taxes, continuing operations 274 -77 – 555 384 -31 Income taxes -47 -25 -166 -127 Income after taxes, continuing operations 227 -102 – 389 257 -34 Income after taxes, discontinued operations – – -1 – Income after taxes 227 -102 – 388 257 -34 thereof income attributable to non-controlling interests 4 4 14 10 Net income 223 -106 – 374 247 -34 Earnings per share in € 0.48 -0.23 0.80 0.53 388 577 578 522 448 509 560 0 100 200 300 400 500 600 Q4 Q3 Q2 Q1 Adjusted EBITDA by quarter 2025 2024 in € million 4 QUARTERLY STATEMENT Q3 2025 EVONIK The adjustments of -€222 million contained -€31 million for structural measures, especially for projects to optimize individual businesses. The other special items of -€191 million mainly comprised impairment losses on assets in the Infrastructure segment. In the previous year’s adjustments, the expenses in connection with the sale of the Superabsorbents business in August 2024 were offset by income from the reversal of an impairment loss on a production facility in the Advanced Technologies segment. The financial result declined by €4 million to -€52 million. Income before income taxes, continuing operations was -€77 million, which was well below the prior-year level of €274 million as a result of the weaker business performance and impairment losses. Due to non-deductible expenses, income taxes amounted to €25 million. Net income declined from €223 million to -€106 million. After adjustment for special items, adjusted net income decreased by 53 percent to €128 million. Adjusted earnings per share dropped from €0.58 in the prior-year period to €0.27. Reconciliation to adjusted net income 3rd quarter 1st nine months in € million 2024 2025 Change in % 2024 2025 Change in % Adjusted EBITDA 577 448 -22 1,677 1,517 -10 Adjusted depreciation, amortization, and impairment losses -255 -251 -761 -761 Adjusted EBIT 322 197 -39 916 756 -17 Adjusted financial result -48 -52 -112 -126 Adjusted amortization and impairment losses on intangible assets 34 33 104 99 Adjusted income before income taxesa 308 178 -42 908 729 -20 Adjusted income taxes -33 -46 -192 -156 Adjusted income after taxesa 275 132 -52 716 573 -20 thereof adjusted income attributable to non-controlling interests 4 4 14 10 Adjusted net incomea 271 128 -53 702 563 -20 Adjusted earnings per share in €a 0.58 0.27 1.51 1.21 a Continuing operations. Business performance in the first nine months of 2025 Sales decreased by 8 percent to €10,666 million. The organic decline in sales of 4 percent principally resulted from lower volumes. Other contributory factors were negative currency effects and the sale of the Superabsorbents business as of August 31, 2024. Adjusted EBITDA contracted by 10 percent to €1,517 million. That was mainly due to lower selling prices, declining volumes, and negative currency effects, while one-time income and lower variable costs mitigated the downward trend. The adjusted EBITDA margin fell from 14.5 percent in the first nine months of 2024 to 14.2 percent. EVONIK QUARTERLY STATEMENT Q3 2025 5 The adjustments of -€246 million contained -€36 million for structural measures, especially for projects to optimize individual businesses. The other special items amounted to -€203 million and mainly comprised impairment losses on assets in the Infrastructure segment. The prior-year adjustments of -€249 million were due principally to structural measures, mainly for the internal Evonik Tailor Made program and in connection with the sale of the Superabsorbents business in August 2024. The financial result was -€126 million, which was below the prior-year level of -€112 million, which contained positive effects from accounting for hyperinflationary economies. Income before income taxes, continuing operations decreased by 31 percent to €384 million. Income tax expense amounted to €127 million. Overall, net income fell 34 percent to €247 million due to the drop in operating income. Adjusted net income declined by 20 percent to €563 million, and adjusted earnings per share decreased from €1.51 to €1.21. Performance of the segments Advanced Technologies Key figures 3rd quarter 1st nine months in € million 2024 2025 Change in % 2024 2025 Change in % External sales 1,535 1,445 -6 4,585 4,557 -1 Adjusted EBITDA 296 202 -32 838 759 -9 Adjusted EBITDA margin in % 19.3 14.0 – 18.3 16.7 – Adjusted EBIT 186 89 -52 503 421 -16 Capital expendituresa 77 72 -6 224 210 -6 No. of employees as of September 30 – – – 9,647 9,189 -5 Prior-year figures restated. a Capital expenditures for intangible assets, property, plant and equipment. In the Advanced Technologies segment, sales contracted by 6 percent to €1,445 million in the third quarter of 2025. This was attributable to slightly lower volumes and selling prices as well as to negative currency effects. There was a considerable reduction in sales in the Animal Nutrition business, mainly as a consequence of lower volumes, the reduction in methionine prices, which had been expected, and negative currency effects. In the Inorganics business, sales were lower than in the prior-year period due to a drop in volumes and currency effects. Sales were up slightly year-on-year in the Organics business, where high-performance polymers benefited from significantly positive demand, for example, for membranes. Despite the persistently high competitive pressure, crosslinkers posted higher volumes. 6 QUARTERLY STATEMENT Q3 2025 EVONIK Prior-year figures restated. Adjusted EBITDA dropped 32 percent to €202 million in the Advanced Technologies segment, mainly due to the costs for planned maintenance work. The adjusted EBITDA margin fell from 19.3 percent in the third quarter of 2024 to 14.0 percent. Prior-year figures restated. In the first nine months of 2025, sales in the Advanced Technologies segment contracted slightly year-on-year to €4,557 million. The impact of slightly higher volumes and one-time income was almost entirely canceled out by a slight decline in prices and negative currency effects. Adjusted EBITDA decreased by 9 percent to €759 million, mainly because of the reduction in selling prices. The adjusted EBITDA margin fell from 18.3 percent in the first nine months of 2024 to 16.7 percent. 1,504 1,535 1,533 1,517 1,445 1,511 1,601 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 Q4 Q3 Q2 Q1 Sales Advanced Technologies 2025 2024 in € million 185 296 267 275 202 266 291 0 50 100 150 200 250 300 Q4 Q3 Q2 Q1 Adjusted EBITDA Advanced Technologies 2025 2024 in € million EVONIK QUARTERLY STATEMENT Q3 2025 7 Custom Solutions Key figures 3rd quarter 1st nine months in € million 2024 2025 Change in % 2024 2025 Change in % External sales 1,465 1,340 -9 4,329 4,133 -5 Adjusted EBITDA 287 215 -25 799 726 -9 Adjusted EBITDA margin in % 19.6 16.0 – 18.5 17.6 – Adjusted EBIT 210 140 -33 571 501 -12 Capital expendituresa 71 72 1 179 200 12 No. of employees as of September 30 – – – 9,786 9,644 -1 Prior-year figures restated. a Capital expenditures for intangible assets, property, plant and equipment. Sales in the Custom Solutions segment dropped 9 percent to €1,340 million in the third quarter of 2025 as a result of lower volumes and negative currency effects, while slightly higher selling prices held back the decline. In the Additives business, there was a significant drop in demand for additives for polyurethane foams and consumable durables. Products for the paints and coatings industry were affected by a considerable reduction in volumes. Oil additives posted stable demand and slightly higher selling prices. Overall, sales of additives declined considerably. The Care business also registered a volume-driven reduction in sales compared to the prior-year period despite slightly higher selling prices. Prior-year figures restated. 1,408 1,465 1,472 1,392 1,340 1,367 1,427 0 200 400 600 800 1,000 1,200 1,400 1,600 Q4 Q3 Q2 Q1 Sales Custom Solutions 2025 2024 in € million 8 QUARTERLY STATEMENT Q3 2025 EVONIK Adjusted EBITDA decreased by 25 percent to €215 million, mainly because of lower demand. The adjusted EBITDA margin fell from 19.6 percent in the third quarter of 2024 to 16.0 percent. Prior-year figures restated. In the first nine months of 2025, sales fell 5 percent to €4,133 million in the Custom Solutions segment. This was attributable to lower volumes and negative currency effects, while selling prices increased slightly. Adjusted EBITDA dropped 9 percent to €726 million, driven mainly by volumes. The adjusted EBITDA margin was 17.6 percent, which was below the previous year’s good level (18.5 percent). Infrastructure Key figures 3rd quarter 1st nine months in € million 2024 2025 Change in % 2024 2025 Change in % External sales 771 574 -26 2,460 1,867 -24 Adjusted EBITDA 68 54 -21 242 154 -36 Adjusted EBITDA margin in % 8.8 9.4 – 9.8 8.2 – Adjusted EBIT 27 16 -41 123 30 -76 Capital expendituresa 14 21 50 43 53 23 No. of employees as of September 30 – – – 3,906 3,848 -1 Prior-year figures restated. a Capital expenditures for intangible assets, property, plant and equipment. In the third quarter of 2025, sales in the Infrastructure segment were €574 million, 26 percent lower than in the prior-year period, which still contained sales from the Superabsorbents business, which was sold at the end of August 2024. In addition, the Oxeno business reported a significant drop in sales as a consequence of lower volumes and declining selling prices. Adjusted EBITDA decreased by 21 percent to €54 million. In the first nine months of 2025, sales declined by 24 percent to €1,867 million. This was principally due to portfolio adjustments. Adjusted EBITDA decreased by 36 percent to €154 million due to the weaker performance of the Oxeno business. 179 287 281 231 215 254 256 0 50 100 150 200 250 300 Q4 Q3 Q2 Q1 Adjusted EBITDA Custom Solutions 2025 2024 in € million EVONIK QUARTERLY STATEMENT Q3 2025 9 Financial position Compared with the first nine months of 2024, the cash flow from operating activities, continuing operations decreased by €444 million to €831 million. This was primarily due to a weaker operating performance than in the prior-year period and higher bonus payments for 2024. Cash outflows for investments in intangible assets, property, plant and equipment were reduced by €27 million to €547 million. The free cash flow fell by €417 million to €284 million. Cash flow statement (excerpt) 1st nine months in € million 2024 2025 Cash flow from operating activities, continuing operations 1,275 831 Cash outflows for investments in intangible assets, property, plant and equipment -574 -547 Free cash flow 701 284 Cash flow from other investing activities, continuing operations 117 64 Cash flow from financing activities, continuing operations -1,100 -331 Change in cash and cash equivalents -283 17 Net financial debt was €3,677 million, an increase of €424 million compared with December 31, 2024. This was mainly attributable to the regular payment of the dividend for the previous fiscal year in the second quarter (€545 million). Net financial debt in € million Dec. 31, 2024 Sep. 30, 2025 Non-current financial liabilitiesa -2,961 -3,482 Current financial liabilitiesa -883 -771 Financial debt -3,844 -4,253 Cash and cash equivalents 461 454 Current securities 128 121 Other financial investments 2 1 Financial assets 591 576 Net financial debt -3,253 -3,677 a Excluding derivatives and excluding the liabilities under rebate and bonus agreements. A conventional bond with a nominal value of €500 million, which matured in September 2025, was redeemed. Evonik had already secured the refinancing by issuing a green bond with a nominal value of €500 million in January 2025. Compared with December 31, 2024, financial debt increased by €409 million to €4,253 million. This resulted primarily from the issuance of additional short-term commercial paper (€270 million) and a slight rise in liabilities for bonds (€172 million). This increase was attributable to contrary effects: In September 2025 Evonik issued a green hybrid bond with a nominal value of €500 million and a tenor of 30 years. This has an annual coupon of 4.25 percent and Evonik has a first right of redemption in 2031. The aim was to secure the early refinancing of a green hybrid bond with the same nominal value issued in 2021 which gives Evonik a first right of redemption between September 2026 and December 2026. 10 QUARTERLY STATEMENT Q3 2025 EVONIK In addition, Evonik made a tender offer to investors of this outstanding hybrid bond in September 2025. The take-up rate was around 66 percent. Therefore, a nominal amount of €328 million was repaid to holders of the outstanding bond ahead of schedule in September 2025. Consequently, the net outstanding liability for hybrid bonds increased by €172 million as of September 30, 2025. Capital expenditures for intangible assets, property, plant and equipment amounted to €490 million in the first nine months of 2025 (9M 2024: €485 million). In principle, there is a slight timing difference in cash outflows for intangible assets, property, plant and equipment. Current major projects include the expansion of production capacities for SEPURAN® membranes in Austria and the construction of an aluminum oxide plant in Japan. Expected development Our expectations for global economic conditions in 2025 are essentially unchanged from mid-year. Since the economic situation entails extremely high uncertainty, we assume weak global GDP growth. Although there has been a slight reduction in the uncertainty caused by the statements of intent regarding US trade policy with major trading partners, the negative consequences are becoming increasingly visible, and the global economy has been losing momentum, especially since mid- year. The introduction or expansion of import duties will hold back growth in all regions, especially North America. The economic outlook depends, above all, on the future US economic and trade policy and possible retaliation by trading partners. Moreover, growth potential is being held back by structural challenges such as high global debt, the real estate crisis in China, and structurally high energy costs in Europe. Ultimately, the development of the global economy could be below our expectations as a result of a financial or real estate crisis, expansion of the geopolitical conflicts, or a further significant rise in energy costs. The economy should be supported by the interest cuts made to date by the ECB and other central banks. There will be a time lag before the Fed’s first interest rate cut of this year, in September, starts to have a positive impact on the US economy. Consumer spending should benefit from the improvement in financing terms and, in Europe in particular, from a renewed rise in real wages and the continued robustness of the labor market. The planned additional spending on infrastructure and defense in Germany will not have a noticeable effect on economic growth in 2025. In view of the very high volatility caused by trade policy developments, we expect that in 2025 the prices of the specific raw materials used by Evonik will be similar to the prior-year level. Expected development of earnings The economic background remained challenging in recent months. While the prolonged phase of low growth impetus and weak demand continued in key end-markets, additional uncertainty came from the protectionist US trade policy. The resulting depreciation of the US dollar also had a negative effect. Following a good start to the year, these factors have been affecting our performance since the second quarter. The weak earnings in May and June continued in the summer months. EVONIK QUARTERLY STATEMENT Q3 2025 11 Moreover, the hopes of a slight economic upturn from September have not materialized. Customers in all segments and almost all end-markets are very cautious. We do not expect the generally weak demand situation to change in the remainder of this year. Therefore, Evonik is working continuously to remain successful, regardless of external factors. As in previous years, this is supported principally by our strong focus on cost discipline. The realization of a wide range of cost-cutting and optimization programs, both in our administration and in our operating business, is already visible in the reduction in our headcount. In addition, our global alignment, our position in attractive niches and our innovation growth areas, and the increasing utilization of production capacities completed in recent years will have a positive effect in the mid-term. Alongside the gloomy macroeconomic situation, which is reflected above all in the Oxeno business (C4 chemistry), strong downside influences are still coming from the negative currency effects caused by the US dollar. On this basis, Evonik now expects adjusted EBITDA to be around €1.9 billion (previously: €2.0 billion to €2.3 billion; 2024: €2,065 million). In 2025, the return on capital employed (ROCE) is expected to be slightly below the prior-year level (previously: around the prior-year level; 2024: 7.1 percent). Development of the segments For most businesses in the Advanced Technologies segment, we expect the ongoing phase of weak demand in our markets to continue in the remainder of 2025. The differentiated steering of the businesses resulting from our new corporate structure means that Advanced Technologies is concentrating primarily on ensuring high utilization of production capacities. In the Organics business, we should benefit from the continued ramp-up of new capacities for high-performance polymers, but Crosslinkers will continue to feel strong competitive pressure. For the Animal Nutrition business, a slight normalization of prices of essential amino acids will be noticeable compared with the prior year, but this will not be as strong as had been anticipated at the beginning of the year. Since the market will continue its solid, long-term volume growth, higher volumes, supported by our extended production capacities in Singapore, should partially offset the price erosion. Additionally, we will further optimize our cost positions in the various businesses in this segment. Overall, we still anticipate that earnings in the Advanced Technologies segment will be slightly below the prior-year level (2024: €1,023 million). In 2025, the Additives business in the Custom Solutions segment will continue to benefit from its specific customer solutions, which are geared to improving product properties and sustainability profiles. Following a significant improvement last year, its development has been less dynamic this year due to the macroeconomic slowdown. In the Care business, our system solutions for active cosmetic ingredients should continue their profitable growth, despite short-term restraint in demand for specialties. We will deliver further batches of our innovative rhamnolipids (biosurfactants) to our customers from the new production plant in Slovakia, which came on stream last year. The development of the basic business, for instance, for domestic cleaning agents, is expected to be weaker. The differentiated steering of the businesses resulting from the new corporate structure is also visible in this segment: The drop in volumes is largely offset by stable prices. Consequently, we now anticipate that this segment’s earnings will be around the prior-year level (previously: rise slightly year-on-year; 2024: €978 million). For the Infrastructure segment (including Oxeno/C4 chemicals) and Others, we are still forecasting a significant year-on- year reduction in earnings in 2025 (2024: €64 million). We assume that the savings measures introduced will have a positive effect on both Infrastructure and Others. However, this is likely to be overshadowed by the weak demand in the Oxeno (C4 chemicals) business. 12 QUARTERLY STATEMENT Q3 2025 EVONIK Financing and investments In view of the challenging macroeconomic situation, in the second quarter, Evonik reduced planned investments in intangible assets, property, plant and equipment to around €750 million (2024: €840 million). This keeps us well below the long-term average, and our disciplined spending will ensure a high free cash flow in 2025. However, as well as impacting earnings, since the second quarter the ongoing weak demand has meant that working capital has not been reduced to the extent originally anticipated. Another countereffect is the higher bonus payments for the successful performance in 2024. Consequently, we now anticipate that the cash conversion rate will be between 30 percent and 40 percent in 2025 (previous target: around 40 percent; 2024: 42 percent; absolute free cash flow: €873 million). Forecast for 2025 Forecast performance indicators 2024 Forecast for 2025a Revised forecast for 2025b Current forecast for 2025 Adjusted EBITDA €2.1 billion Between €2.0 billion and €2.3 billion At the lower end of the €2.0 billion to €2.3 billion range Around €1.9 billion ROCE 7.1% Above the prior year At the prior-year level Slightly below the prior-year level Cash outflows for investments in intangible assets, property, plant and equipment €840 million Around €850 million Around €750 million Around €750 million Free cash flow: cash conversion ratec 42% Around 40% Around 40% Between 30% and 40% a As reported in the financial and sustainability report 2024. b As reported in the half year financial report 2025. c Ratio of free cash flow to adjusted EBITDA. EVONIK QUARTERLY STATEMENT Q3 2025 13 Income statement 3rd quarter 1st nine months in € million 2024 2025 2024 2025 Sales 3,832 3,391 11,558 10,666 Cost of sales -2,804 -2,775 -8,484 -8,111 Gross profit on sales 1,028 616 3,074 2,555 Selling expenses -468 -420 -1,414 -1,308 Research and development expenses -106 -104 -326 -315 General administrative expenses -128 -111 -611 -362 Other operating income 83 54 198 180 Other operating expense -90 -61 -265 -245 Result from investments recognized at equity 3 1 11 5 Income before financial result and income taxes, continuing operations (EBIT) 322 -25 667 510 Interest income 8 7 36 42 Interest expense -53 -56 -158 -164 Other financial income/expense -3 -3 10 -4 Financial result -48 -52 -112 -126 Income before income taxes, continuing operations 274 -77 555 384 Income taxes -47 -25 -166 -127 Income after taxes, continuing operations 227 -102 389 257 Income after taxes, discontinued operations – – -1 – Income after taxes 227 -102 388 257 thereof attributable to non-controlling interests 4 4 14 10 thereof attributable to shareholders of Evonik Industries AG (net income) 223 -106 374 247 Earnings per share in € (basic and diluted) 0.48 -0.23 0.80 0.53 thereof continuing operations 0.48 -0.23 0.80 0.53 thereof discontinued operations 0.00 0.00 0.00 0.00 14 QUARTERLY STATEMENT Q3 2025 EVONIK Balance sheet in € million Dec. 31, 2024 Sep. 30, 2025 Goodwill 4,707 4,415 Other intangible assets 864 716 Property, plant and equipment 6,450 5,933 Right-of-use assets 947 893 Investments recognized at equity 49 45 Trade accounts receivable – 54 Other financial assets 467 418 Deferred taxes 664 659 Other income tax assets 25 22 Other non-financial assets 69 87 Non-current assets 14,242 13,242 Inventories 2,662 2,555 Trade accounts receivable 1,622 1,581 Other financial assets 216 266 Other income tax assets 166 86 Other non-financial assets 381 363 Cash and cash equivalents 461 454 Current assets 5,508 5,305 Total assets 19,750 18,547 Issued capital 466 466 Capital reserve 1,168 1,168 Retained earnings 7,426 7,412 Other equity components -40 -697 Equity attributable to shareholders of Evonik Industries AG 9,020 8,349 Equity attributable to non-controlling interests 80 64 Equity 9,100 8,413 Provisions for pensions and other post-employment benefits 1,662 1,387 Other provisions 734 667 Other financial liabilities 3,162 3,663 Deferred taxes 638 629 Other income tax liabilities 254 246 Other non-financial liabilities 141 95 Non-current liabilities 6,591 6,687 Other provisions 923 724 Trade accounts payable 1,600 1,359 Other financial liabilities 1,034 830 Other income tax liabilities 87 59 Other non-financial liabilities 415 475 Current liabilities 4,059 3,447 Total equity and liabilities 19,750 18,547 EVONIK QUARTERLY STATEMENT Q3 2025 15 Cash flow statement 3rd quarter 1st nine months in € million 2024 2025 2024 2025 Income before financial result and income taxes, continuing operations (EBIT) 321 -25 667 510 Depreciation, amortization, impairment losses/reversal of impairment losses on non-current assets 234 428 749 928 Result from investments recognized at equity -3 – -11 -5 Gains/losses on the disposal of non-current assets 21 5 17 24 Change in inventories -99 94 -351 -39 Change in trade accounts receivable 118 52 -97 -107 Change in trade accounts payable -180 -67 70 -110 Change in provisions for pensions and other post-employment benefits – -28 -44 -45 Change in other provisions 126 40 394 -264 Change in miscellaneous assets/liabilities 16 7 -36 -15 Cash inflows from dividends 1 – 21 19 Cash outflows for income taxes -101 -43 -213 -152 Cash inflows from income taxes 83 18 109 87 Cash flow from operating activities, continuing operations 537 481 1,275 831 Cash outflows for investments in intangible assets, property, plant and equipment -180 -181 -574 -547 Cash outflows to obtain control of businesses – – -15 – Cash outflows relating to the loss of control over businesses -11 -1 -13 -2 Cash outflows for investments in other shareholdings -3 – -6 – Cash inflows from divestments of intangible assets, property, plant and equipment -5 1 14 9 Cash inflows relating to the loss of control over businesses 17 – 20 9 Cash inflows from divestment of other shareholdings – – – 3 Cash inflows/outflows relating to securities, deposits, and loans 85 164 86 12 Cash inflows from interest 11 6 31 33 Cash flow from investing activities, continuing operations -86 -11 -457 -483 Capital inflows from/outflows to non-controlling interests – – – 4 Cash outflows for dividends to shareholders of Evonik Industries AG – – -545 -545 Cash outflows for dividends to non-controlling interests – -4 -16 -9 Cash outflows due to changes in ownership interests in subsidiaries – – – -19 Cash outflows for the purchase of treasury shares – – -12 -1 Cash inflows from the sale of treasury shares – – 9 1 Cash inflows from the addition of financial liabilities 487 921 640 1,736 Cash outflows for repayment of financial liabilities -946 -1,252 -1,093 -1,424 Cash inflows/outflows in connection with financial transactions 7 – 1 5 Cash outflows for interest -52 -53 -84 -79 Cash flow from financing activities, continuing operations -504 -388 -1,100 -331 Change in cash and cash equivalents -53 82 -283 17 Cash and cash equivalents as of July 1/January 1 518 379 749 461 Change in cash and cash equivalents -53 82 -283 17 Changes in exchange rates and other changes in cash and cash equivalents -5 -7 -6 -24 Cash and cash equivalents as on the balance sheet as of September 30 460 454 460 454 16 QUARTERLY STATEMENT Q3 2025 EVONIK Segment report Segment report by operating segments—3rd quarter Advanced Technologies Custom Solutions in € million 2024 2025 2024 2025 External sales 1,535 1,445 1,465 1,340 Internal sales 13 21 31 27 Total sales 1,548 1,466 1,496 1,367 Adjusted EBITDA 296 202 287 215 Adjusted EBITDA margin in % 19.3 14.0 19.6 16.0 Adjusted EBIT 186 89 210 140 Capital expendituresa 77 72 71 72 Financial investments – – – – Prior-year figures restated. a For intangible assets, property, plant and equipment. Segment report by regions—3rd quarter Europe, Middle East & Africa Americas in € million 2024 2025 2024 2025 External salesa 1,839 1,609 1,159 1,016 Capital expenditures 96 97 49 58 Prior-year figures restated. a External sales Europe, Middle East & Africa: thereof Germany €609 million (Q3 2024: €646 million). EVONIK QUARTERLY STATEMENT Q3 2025 17 Infrastructure Enabling functions, other activities, consolidation Total Group (continuing operations) 2024 2025 2024 2025 2024 2025 771 574 61 32 3,832 3,391 210 99 -254 -147 – – 981 673 -193 -115 3,832 3,391 68 54 -74 -23 577 448 8.8 9.4 – – 15.1 13.2 27 16 -101 -48 322 197 14 21 18 8 180 173 – – 3 2 3 2 Asia-Pacific Total Group (continuing operations) 2024 2025 2024 2025 834 766 3,832 3,391 35 18 180 173 18 QUARTERLY STATEMENT Q3 2025 EVONIK Segment report by operating segments—1st nine months Advanced Technologies Custom Solutions in € million 2024 2025 2024 2025 External sales 4,585 4,557 4,329 4,133 Internal sales 58 70 98 85 Total sales 4,643 4,627 4,427 4,218 Adjusted EBITDA 838 759 799 726 Adjusted EBITDA margin in % 18.3 16.7 18.5 17.6 Adjusted EBIT 503 421 571 501 Capital expendituresa 224 210 179 200 Financial investments 16 – – – No. of employees as of September 30 9,647 9,189 9,786 9,644 Prior-year figures restated. a For intangible assets, property, plant and equipment. Segment report by regions—1st nine months Europe, Middle East & Africa Americas in € million 2024 2025 2024 2025 External salesa 5,642 5,118 3,420 3,131 Non-current assets in accordance with IFRS 8 as of September 30 6,954 6,564 4,198 4,057 Capital expenditures 265 259 142 173 No. of employees as of September 30 21,468 20,777 5,487 5,544 Prior-year figures restated. a External sales Europe, Middle East & Africa: thereof Germany €1,981 million (9M 2024: €1,983 million). EVONIK QUARTERLY STATEMENT Q3 2025 19 Infrastructure Enabling functions, other activities, consolidation Total Group (continuing operations) 2024 2025 2024 2025 2024 2025 2,460 1,867 184 109 11,558 10,666 637 357 -793 -512 – – 3,097 2,224 -609 -403 11,558 10,666 242 154 -202 -122 1,677 1,517 9.8 8.2 – – 14.5 14.2 123 30 -281 -196 916 756 43 53 39 27 485 490 – – 6 4 22 4 3,906 3,848 8,701 8,616 32,040 31,297 Asia-Pacific Total Group (continuing operations) 2024 2025 2024 2025 2,496 2,417 11,558 10,666 1,540 1,469 12,692 12,090 78 58 485 490 5,085 4,976 32,040 31,297 20 QUARTERLY STATEMENT Q3 2025 EVONIK Appendix Restatement of prior-year figures As of October 1, 2024, Evonik integrated the Performance Materials division into the Technology & Infrastructure division, which was renamed the Infrastructure division effective January 1, 2025. The prior-year figures of the former Performance Materials division contain the Superabsorbents business, which was sold as of August 31, 2024, and the integrated C4 products business (Oxeno business line, formerly Performance Intermediates), which is also earmarked for sale. The prior-year figures have been restated accordingly. Integration of the Performance Materials and Technology & Infrastructure divisions to form the Infrastructure division—First nine months of 2024 in € million Performance Materials Technology & Infrastructure Infrastructure Consolidation External sales -1,851 -780 2,631 – Internal sales -187 -1,426 1,146 467 Total sales -2,038 -2,206 3,777 467 Adjusted EBITDA -114 -224 338 – Adjusted EBIT -50 -119 169 – Capital expenditures -19 -56 75 – As of January 1, 2025, Evonik split parts of the Infrastructure division into cross-site technology and site-specific infrastructure activities. The infrastructure activities at the large sites in Marl and Wesseling in Germany remain in the Infrastructure division, along with the Oxeno business line (formerly Performance Intermediates). Further, smaller sites, which often only serve individual business lines, were allocated directly to the respective businesses and thus to the chemicals divisions. The cross-site technology activities are now managed in a newly established function within the Enabling functions. The prior-year figures have been restated accordingly. Restatement of prior–year figures due to the reorganization of Infrastructure—First nine months of 2024 in € million Specialty Additives Nutrition & Care Smart Materials Infrastructure Enabling functions, other activities, consolidation External sales 20 - 4 -171 147 Internal sales 130 82 5 -509 292 Total sales 150 82 9 -680 439 Adjusted EBITDA 36 13 6 -96 41 Adjusted EBIT 20 7 4 -46 15 Capital expenditures 15 8 1 -32 8 EVONIK QUARTERLY STATEMENT Q3 2025 21 Effective April 1, 2025, Evonik aligned its corporate structure with the strategic development of the Group and introduced a considerably leaner management model. The previous 14 chemicals business lines, which were assigned to three divisions, are now bundled in two segments managed directly by individual members of the executive board. They are now managed in a more differentiated manner based on their business models and strategic roles. The new Advanced Technologies segment comprises technology- and efficiency-driven businesses, while the new Custom Solutions segment comprises solution- and innovation-driven businesses. This sharpens the strategy and allows a corresponding allocation of resources. The former division management level has been eliminated. Restatement of prior–year figures due to the new corporate structure—First nine months of 2024 in € million Specialty Additives Nutrition & Care Smart Materials Advanced Technologies Custom Solutions Consolidation External sales -2,770 -2,802 -3,342 4,585 4,329 – Internal sales -134 -88 -32 58 98 98 Total sales -2,904 -2,890 -3,374 4,643 4,427 98 Adjusted EBITDA -649 -488 -500 838 799 – Adjusted EBIT -498 -322 -254 503 571 – Capital expenditures -86 -179 -138 224 179 – Impairment test pursuant to IAS 36 In the challenging economic conditions in 2025, Evonik has not performed as well as had been anticipated at the beginning of the year. This triggered impairment tests on other intangible assets, property, plant and equipment, right-of-use assets, investments recognized at equity, and certain other non-financial assets as of September 30, 2025. In the Infrastructure segment, the impairment test on the Oxeno cash generating unit (CGU) resulted in an impairment loss of €170 million for the production facilities in Germany and Belgium. This related to property, plant and equipment, especially plant and machinery. 22 QUARTERLY STATEMENT Q3 2025 EVONIK Financial calendar Financial calendar 2026 Event Date Report on Q4 2025 and FY 2025 March 4, 2026 Interim report Q1 2026 May 8, 2026 Annual shareholders’ meeting 2026 June 3, 2026 Interim report Q2 2026 August 4, 2026 Interim report Q3 2026 November 3, 2026 Credits Published by Evonik Industries AG Rellinghauser Strasse 1–11 45128 Essen, Germany www.evonik.com Contact Communications Phone +49 201 177-3315 presse@evonik.com Investor Relations Phone +49 201 177-3146 investor-relations@evonik.com The English version of this quarterly statement is a translation of the German original report and is provided for information only.